Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Prenetics Holding Company Limited (PRENW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/31/2025: PRENW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -24.07% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/31/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 14668 | Beta -0.31 | 52 Weeks Range 0.01 - 0.02 | Updated Date 02/26/2025 |
52 Weeks Range 0.01 - 0.02 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -183.52% | Operating Margin (TTM) -151.82% |
Management Effectiveness
Return on Assets (TTM) -11.06% | Return on Equity (TTM) -23.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 8956477 |
Shares Outstanding - | Shares Floating 8956477 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Prenetics Holding Company Limited
Company Overview
History and Background
Prenetics Holding Company Limited was founded in 2013 in Hong Kong. It started as a genetic testing company focused on early disease detection. It has evolved into a global leader in diagnostics and personalized and preventative healthcare.
Core Business Areas
- Diagnostics: Provides comprehensive genetic testing services for cancer, cardiovascular diseases, and inherited conditions. They offer early screening for diseases and individualized health plans.
- Prevention: Focuses on offering a data-driven approach to health management and providing people with tools to take control of their health.
- CircleDNA: A direct-to-consumer (DTC) genetic testing kit that provides insights into an individual's health, including ancestry, diet, fitness, and disease risk.
Leadership and Structure
The leadership team is led by CEO Danny Yeung. The company operates with a global structure, with offices and operations in Asia, Europe, and the United States. The company employs a matrix structure.
Top Products and Market Share
Key Offerings
- CircleDNA: A comprehensive DNA test kit offering personalized insights on health and ancestry. No clear market share data is available. Competitors include 23andMe (ME) and AncestryDNA (private).
- ColoClear by Circle: A non-invasive stool DNA test for colorectal cancer screening. Market share data is unavailable. Competitors include Exact Sciences (EXAS) and Guardant Health (GH).
Market Dynamics
Industry Overview
The diagnostics industry is rapidly growing, driven by increasing awareness of personalized medicine and early disease detection. Factors like the aging population and advances in genetic technology are contributing to industry growth. This also leads to increasing competition.
Positioning
Prenetics is positioned as a global leader in personalized and preventative healthcare. It has a competitive advantage in the Asian market and has growing prescence in the US and Europe.
Total Addressable Market (TAM)
The global molecular diagnostics market is projected to reach USD 23.5 Billion by 2028. Prenetics is expanding its product offerings and geographic presence to capitalize on this TAM.
Upturn SWOT Analysis
Strengths
- Strong brand recognition in Asia.
- Innovative and comprehensive product portfolio.
- Direct-to-consumer approach with CircleDNA.
- Focus on preventative healthcare.
- Expanding global presence.
Weaknesses
- Limited market share in the U.S. compared to competitors.
- Dependence on key partnerships.
- Profitability concerns.
- High marketing expenses.
Opportunities
- Expanding product offerings for disease screening.
- Strategic partnerships with healthcare providers.
- Growing awareness of preventative healthcare.
- Increased demand for genetic testing.
- Expansion into new geographic markets.
Threats
- Intense competition from established players.
- Regulatory challenges and compliance.
- Data privacy and security concerns.
- Potential price wars.
- Technological disruptions.
Competitors and Market Share
Key Competitors
- EXAS
- GH
- ME
Competitive Landscape
Prenetics faces intense competition from established players like Exact Sciences and Guardant Health. The company differentiates itself through its direct-to-consumer approach and personalized healthcare solutions.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Prenetics has experienced growth, driven by expansion in the Asian market.
Future Projections: Future growth is projected through global expansion, new partnerships, and product innovation.
Recent Initiatives: Recent initiatives include partnerships with healthcare providers, product launches in the US, and investments in R&D.
Summary
Prenetics Holding Company Limited is a growing global player in diagnostics and personalized healthcare. It shows solid brand strength in Asia and innovative products like CircleDNA. The company faces competition from bigger companies in the United States and must look to expand into new markets. The company is also facing profitability challenges and need to ensure regulatory compliance.
Similar Companies
- EXAS
- GH
- ME
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Financial News Articles
- Analyst Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prenetics Holding Company Limited
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-05-18 | Co-Founder, Chairperson & CEO Mr. Sheng Wu Yeung | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 320 | Website https://www.prenetics.com |
Full time employees 320 | Website https://www.prenetics.com | ||
Prenetics Global Limited, a health sciences company, focuses on advancing consumer and clinical health. The company's consumer initiatives is led by IM8, a new health and wellness brand. Its prevention arm, CircleDNA, uses next-generation sequencing (NGS) technology to offer comprehensive consumer DNA test. It also develops and commercializes multi-cancer early detection technologies. In addition, the company offers a range of genomic profiling panels tailored for requirements and clinician needs, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests. Further, the company offers ACTLiquid Pro, a sequencing based liquid biopsy assay for pan-solid tumors; ACTMonitor, which provides real time monitoring of drug resistance, treatment response, and cancer recurrence; and ACT Risk, which manages the cancer risk. Additionally, it is involved in the sports distribution activities providing sports nutrition products to fitness facilities. The company operates in Taiwan, Hong Kong, the United Kingdom, and internationally. The company was founded in 2014 and is based in Quarry Bay, Hong Kong and has a presence in the United States.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.